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Background: Mammaglobin is expressed mainly in mammary tissue, overexpressed in breast cancer (BC) and
rarely in other tissue. The aim of this study was to assess the sensitivity and specificity of transcript MGB1 detection
and to evaluate the role of MGB1 as potential clinical marker for the detection of disseminated cancer cells in the
blood of BC patients.
Patients and methods: A consecutive series of 23 BC tissues, 36 peripheral blood BC samples and 35 healthy
peripheral blood samples was prospectively recruited to investigate MGB1 expression by means of a quantitative Real
Time RT-PCR assay.
Results: MGB1 overexpression in tissue samples of BC patients is significantly associated only with high level of Ki67
(P <0.05). None of the samples from peripheral blood of 35 healthy female individuals were positive for MGB1
transcript. In contrast MGB1 mRNA expression was detected in three of 36 (8%) peripheral blood of BC patients.
Conclusions: Our preliminary results demonstrate that the detection of MGB1 transcript in peripheral blood of BC
patients was specific but with low sensitivity. MGB1 overexpression by itself or in combination with Ki67 might be
considered an index of BC progression.
Key words: mammaglobin (MGB1), breast cancer, disseminated cancer cells, real time RT-PCR
introduction
Breast carcinoma (BC) is the most common type of neoplasia
found in women from highly industrialized countries in the
Western world [1]. At the moment of diagnosis, most patients
with BC do not present metastases and can therefore be
operated on with high hopes of a favorable outcome.
Nevertheless, in spite of the strong probability of operative
success, 30% of stage I and II patients subsequently regress and
die from the disease [2].
Different approaches, both cellular and molecular, have been
used for the detection of tumor cells in the blood and it is
generally maintained that the technique based on PCR are
more sensitive [3].
In spite of the fact that it has been shown that many
circulating cells are apoptotic [4], a fraction of these prove to be
still vital and capable of distant metastasis; one of the indexes of
cell vitality is the possibility of being transcriptionally active.
The presence of circulating tumor cells in the blood might,
therefore, be measured by means of the analysis of the
expression levels of a specific gene. One of the main problems
of this type of analysis is the identification of a specific gene
target whose expression is associated with the tumor cells and
not to an illegitimate transcription of non-epithelial cells [5].
The gene mammaglobin (MGB1) is a member of the
uteroglobin family, localized on chromosome 11q12-13; it
codifies for a glycoprotein of 23 amino acids whose function
is still unknown [6]. This gene is often expressed at basal levels
in normal breast epithelium and overexpressed in 23% of
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primary breast tumors. This overexpression does not appear to
be correlated with histology, tumor grade, tumor stage or
hormone receptor status [7–9]. However, most recent studies
have evaluated a series of breast cancer specimens and have
reported a correlation between high levels of mammoglobin
and expression of estrogen and progesterone receptor, diploid
DNA content, low Ki67 labeling index, low nuclear grade and
the absence of axillary nodal invasion [10, 11].
The frequency of MGB1 mRNA detection in peripheral blood
samples is variable. In fact, while several studies showed that
MGB1 mRNA could be detected by RT-PCR in the blood of up
to 25% of breast cancer [12, 13], others, using the real time
TaqMan RT PCR approach, identified a MGB1 transcription
level in only 11% of blood samples [14].
The aim of this study was to assess prospectively
mammaglobin expression by means of a quantitative RT-PCR
assay in a consecutive series of 22 BC tissues, correlating the
resulting expression data with available clinical pathological
parameters to clarify the biological role of mammaglobin in BC.
Furthermore, the analysis conducted in this study was used to
test the sensitivity and specificity of mammaglobin transcript
detection by quantitative real time RT-PCR to evaluate the role
of MGB1 as a potential clinical marker for the detection of
disseminated cancer cells in the blood of BC patients.
patients and methods
specimen collection
BC patients who had undergone mastectomy at the Department of
Oncology, University of Palermo, Italy were consecutively recruited for
a prospective study. Tumor and corresponding normal tissue were obtained
from surgical specimens (n = 23). After surgery, the tissue was immediately
submerged in RNAlater (Sigma, St Louis, MO USA) in order to inhibit
ribonuclease and stabilize the RNA, which was then stored at 80C. In
order to avoid evaluator variability in the patients, all resection specimens
were meticulously examined by two independent pathologists who were not
aware of the original diagnosis and of the results of the molecular analyses.
All tumors were histologically confirmed to be BC.
About 2.5 ml of peripheral blood were collected from each of 36
women with BC and of 35 healthy women, in Paxgene blood RNA tubes
(Qiagen, Hilden, Germany) containing an RNA stabilizing solution.
Written informed consent was obtained from all the patients recruited for
the study.
RNA extraction and cDNA synthesis
Total RNA from peripheral blood was extracted with the use of the PAXgene
blood RNA kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions, while total cellular RNA was taken from about 30 mg of tissue,
both tumoral and normal, with the Rneasy Minikit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. The extracted
RNA was stored at 80C until further use.
RNA integrity was verified on the Agilent 2100 bioanalyzer with the use of
the RNA 6000 Nano assay protocol (Agilent Technologies, Palo Alto, CA,
USA). Only samples with an RNA integrity number (RIN) between 8 and
10 were analyzed.
For cDNA synthesis 5 lg of total RNA were reverse transcribed in a final
volume of 50 ll with a High Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA) according to the manufacturer’s instructions.
The samples were incubated for 10 min at 25C and for 2 h at 37C on the
GeneAmp 9700 Applied Biosystem (Applied Biosystems, Foster City, CA).
quantitative determination of MGB1 by real time RT-PCR
Real time RT-PCR was performed with the ABI PRISM 7900 HT
Sequence Detection System (Applied Biosystems, Foster City, CA) using
the TaqManmethod, which takes advantage of the 59–39 exonuclease activity
of the Taq DNA polymerase. In this assay, over the two primers,
a fluorescent probe containing a reporter dye at the 59 end and a quencher
dye at the 39 end was added to the reaction. During PCR, the AmpliTaq
Gold enzyme (Applied Biosystems, Foster City, CA) degrades the probe by
separating the reporter dye from the quencher dye, which results in
increased reporter fluorescence. The accumulation of amplificate is
measured by monitoring the actual fluorescence during the exponential
PCR phase by means of a charge-coupled device (CCD) camera.
Quantification is performed using the threshold cycle (Ct), which is the cycle
during which a significant increase in fluorescence is first detected.
For the detection of MGB1 and for normalization the following
predesigned primer and probe set were used: assay-on-demand Gene
Expression Product, number Hs00267190 m_l, SCGB2A2, and assay-
on-demand Gene Expression Product, number 4333763F, Hu-PPIA,
(Applied Biosystems, Foster City, CA). For the PCR, 100 ng of cDNA in
a final volume of 50 ll of TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, CA) was used according to the manufacturer’s
guidelines.
Each sample was analyzed in triplicate and the mean quantity of each
triplicate calculated by the ABI PRISM 7900 HT Sequence Detection System
(Applied Biosystems, Foster City, CA).
In our study, the comparative Ct method was used to quantify the relative
gene expression with the formula 2DDCt, using cyclophilin A (Hu-PPIA) as
the endogenous control and normal tissue as a calibrator.
statistical analysis
Statistical analyses were performed separately for tissues and blood
samples of BC patients. Associations between mRNA mammaglobin
expression level and clinico-pathological variables were evaluated by the
chi-square test with Yates correction, where appropriate.
results
Patients were all female with a mean age for BC tissue patients of
63.3 years (range 35–81) and for BC peripheral blood patients of
58 years (range 38–82). Table 1 shows the clinicopathological
features of BC patients.
mammaglobin mRNA expression in breast tissue
RNA extracted from 22 samples of BC tissues was analyzed
for MGB! mRNA expression by Real Time RT-PCR. All
samples were positive for the MGB1 transcript with regard to
normal breast tissue and 11/22 (50%) showed overexpression
(above the median for the whole group) (Figure 1).
We used the detection of PPIA mRNA in all reactions to
exclude the fact that the absence of MGB1 expression was due
to degraded RNA.
The statistical analysis of MGB1 mRNA expression in tissue
samples showed that it is associated with higher Ki67 value
but not with histological type, tumor grade, TNM stage and
165 steroid hormone receptor status (Table 2).
mammaglobin mRNA expression in peripheral
blood samples
None of the samples from the peripheral blood of 35 healthy
female patients was positive for MGB1 transcript, while MGB1
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mRNA expression was detected in three of 36 (8%) of peripheral
blood BC patients (Table 3). We used the detection of PPIA
mRNA in all reactions to exclude the fact that the absence of
hMAM expression was due to degraded RNA. Figure 2A shows
the amplification plot for MGB1 expression of one of the three
positive samples, while Figure 2B shows the MGB1 expression
plot of all the three positive samples.
discussion
Even though a great deal of progress has been made in the
chemotherapy strategies used in BC patients, especially in
advanced tumors, leading to considerable improvement in life
style and survival rate, surgical resection remains the most
effective treatment for avoiding disease recurrence. Even so, the
post-operative clinical course of these patients may be negatively
affected by the presence of micrometastases circulating in
peripheral blood, not easy to detect with traditional
anatomopathological techniques [15].
The main clinicopathological factor to take into consideration
in BC treatment is the TNM staging. In particular, a key role is
represented by the T and N values, which indicate tumor size
and lymph node involvement, thus giving an idea of tumor
aggressiveness [16].
The relationship between circulating tumor cells and the
development of metastatic disease is still not fully understood.
In the last few years, a great many biomolecular techniques have
been developed and numerous molecular markers have been
Table 1. Clinicopathological features of breast cancer (BC) patients
Clinicopathological features BC tissue
patients n (%)
BC peripheral blood
patients n (%)
Age (years)
£50 6 (27) 11 (31)
>50 16 (73) 25 (69)
Mean age in years (range) 63.3 (35–81) 58 (38–82)
Tumor histotype
Infiltrating ductal 20 (91) 24 (67)
Infiltrating lobular 0 10 (27)
Infiltrating ductal and lobular 2 (9) 1 (3)
Medullar 0 1 (3)
Lymph node metastasis
Negative 11 (50) 19 (53)
Positive 11 (50) 17 (47)
Histological grade
Well-differentiated (G1) 2 (9) 1 (3)
Moderately-differentiated (G2) 11 (50) 20 (55)
Poorly-differentiated (G3) 9 (41) 15 (42)
Estrogen receptors
Negative 8 (36) 13 (36)
Positive 14 (64) 23 (64)
Progesterone receptors
Negative 8 (36) 13 (36)
Positive 14 (64) 23 (64)
c-ERB
Negative 11 (50) 19 (53)
Positive 11 (50) 17 (47)
Ki67
£20 % 10 (45) 19 (53)
>20 % 12 (55) 17 (47)
Total 22 36 Figure 1. Amplification plot obtained by the ABI PRISM 7900 HT for
MGB1 and PPIA mRNA expression in BC tissue samples relatives to the
tissues with minor (A) and major (B) MGB1 expression. (C) MGB1
expression plot of 22 BC tissue samples.
Table 2. Association between mammaglobin expression and
Ki67 value in 22 breast cancer tissues
Ki67 Low n (%) High n (%) P value
£20% 6 (55) 3 (27)
>20% 2 (18) 8 (73)
Unknown 3 (27) 0
Total 11 11 <0.05
Table 3. Mammaglobin expression in peripheral blood samples of
healthy volunteers and breast cancer (BC) patients
Healthy control
n (%)
BC peripheral blood
sample n (%)
0 (0) 3 (8)
Total 35 36
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identified, making it possible for a clearer classification of
a subgroup of BC patients who might show a more favorable
prognosis and therefore benefit from more specific drug
therapy [17].
The aim of this study was first to analyze the expression
level of the mammaglobin (MGB1) gene in BC tissue samples of
BC patients and in the blood samples of BC patients at any stage
of the disease, in order to identify a possible marker of cancer
aggressiveness and to consider it as a possible index of BC
progression.
The frequency reported for MGB1 expression in BCs varies
from 20% to 80%; such a broad range might be due to several
factors, such as tumor storage methods (fresh/frozen tissue and
paraffin-embedded blocks), the different techniques used for
assessing the different expression levels (RT-PCR, quantitative
real time PCR, immunohistochemical staining, in situ
hybridization), tumoral heterogeneity and the specific features
of the patient cohorts included in the study [7, 9]. For example,
Watson et al. reported overexpression of mammaglobin in only
23% of the breast cancer tissues analyzed. This probably
depends on the low sensitivity of the method utilized, which was
the Northern blot hybridization [8]. In our study, the analysis of
tissue samples has shown that, compared with normal breast
tissue, all the BC tumors also had MGB expression and 50%
(11/22) of the samples showed overexpression. Of these, five of
11 (45%) were node-positive and six of 11 (54%) were node-
negative tissues. The follow-up information of the patients
showing MGB1 overexpression are related to a very short time,
and do not allow for statistical analyses.
Compared with reports in literature, our study shows
a lower rate of MGB1 transcript alteration in the blood samples.
Suchy et al. reported the detection of MGB1 expression in only
11/98 (11%) blood samples of BC patients using the real time
TaqMan RT-PCR approach [14]. In our study no MGB1
expression was ever detected in the 35 peripheral blood samples
obtained from healthy volunteers. This result reinforces the
notion that MGB1 is a specific marker in the identification of
BC cells in peripheral blood. Furthermore, MGB1 expression
was detected in only three of 36 (8%) blood samples obtained
from BC patients at any stage. However, the absence of MGB1
transcript in blood samples does not exclude the presence of
circulating tumor cells; this low rate of MGB1 expression
might possibly have been compromised by the small amount of
blood tested in each reaction, or by the number of cells present
in the peripheral blood or by the MGB1 expression level for
single cells [18].
Recent data also show that the correlation of the MGB1
transcript level with clinical and pathological prognostic
markers is not very clear. While in some cases, in fact, the MGB1
overexpression did not appear to correlate with histological
type, tumor grade, TNM stage or hormone receptor status [8],
in others the overexpression has been associated with a less
aggressive tumor phenotype characterized by a low Ki67 labeling
index, low nuclear grade, estrogen and progesterone receptor
expression [10]. In our study the MGB1 overexpression in the
tissue samples of BC patients seemed to be related only to the
high level of the proliferative index Ki67. The role of
mammaglobin in cancer progression is still unclear [6]. The
finding that MGB1 expression is associated with mammary
gland proliferation and terminal differentiation [19] might
explain our results, if it is considered as strictly correlated with
a process of differentiation brought about by malignant
transformation.
In conclusion, our preliminary results of the analysis of
MGB1 expression level in BC tissue and blood samples obtained
from BC patients show that MGB1 expression is mammary-
specific and may define a unique phenotype to a subset of BC.
Moreover, MGB1 overexpression, by itself or in combination
with Ki67, might be considered a variable index of BC
progression in BC tissues. Additional studies of a long-term
clinical follow-up and larger samples are needed to clarify the
biomolecular, diagnostic and prognostic role of mammaglobin
in BC progression.
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